Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. Advances in understanding treatment resistant cancer cells (part 1).

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

The Pharma Data

APRIL 15, 2022

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

The Pharma Data

SEPTEMBER 29, 2020

Treatment is being developed by Australian biotech Ena Respiratory. A novel nasal spray treatment, being developed by Australian biotech Ena Respiratory, produced promising results against COVID-19 in an animal study performed by Public Health England (PHE) scientists. Source link.

Small Molecule 52

Small Molecule Immune Response Virus Treatment 52

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Executive Vice President, Research, Gilead Sciences. “We The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Discovery World

APRIL 15, 2023

VAL-083, is a ‘first-in-class’ small-molecule chemotherapeutic with a novel mechanism of action that targets DNA and crosses the blood brain barrier to inhibit cancer cell replication and cell division. antibody-drug conjugate, for the treatment of CLDN18.2-expressing Monday, April 17, 2023, 9am ET 4.

Virus 130

Virus Clinical Trials Trials Therapies 130

The Pharma Data

APRIL 22, 2023

These “acute inflammatory lesions” then attract other myeloid cells, as well as self-reactive T and B cells that belong to the immune system’s second arm, known as the “adaptive immune system” and directly attack the myelin covering. “Current MS therapies do not specifically target myeloid cells. .

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Vial

DECEMBER 11, 2023

Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. Two highly effective pan-genotypic DAAs are used worldwide.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

LifeSciVC

MARCH 1, 2023

Learning from Past Failures to Drive Toward a More Durable Immune Response Following the initial clinical successes of blocking inhibitory receptors, like CTLA4 and PD1, many in the immuno-oncology field explored the potential to further enhance anti-tumor immunity by simultaneously enhancing co-stimulatory pathways.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Title: OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase 1 dose-escalation trial. 9:00 – 20:00 Eastern Time.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

Foghorn is anticipating filing an IND later this year for its lead candidate to begin a Phase I trial for the treatment of uveal melanoma, a cancer of the eye. . more than 3,600 new cases of anaplastic glioma are diagnosed each year with a median survival of just over three years despite treatment. Scorpion Therapeutics . In the U.S.,

Small Molecule 52

Small Molecule Immune Response Pharmacokinetics Clinical Development 52

Drug Discovery World

AUGUST 2, 2023

PPT1 inhibitors for the treatment of patients with cancer Contemplating the potential of PPT1 inhibition in cancer led to the development of small molecules with high PPT1 affinity and limited toxicity for clinical drug development. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

Drug Discovery World

SEPTEMBER 6, 2022

Since 2017, a range of approvals by the FDA has resulted in cell therapies – in particular CAR-T-cell therapies – being used in the treatment of blood cancers. I would expect to see more data coming from the use of cell-based treatments for solid tumours such as breast, ovarian, pancreatic or colorectal cancer.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

NIH Director's Blog: Drug Development

MAY 21, 2020

One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules. So, what exactly led up to this latest scientific achievement? In the U.S. medRxiv.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

AUGUST 16, 2021

AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. About Atopic Dermatitis.

Trials 40

Trials Clinical Trials Small Molecule Immune Response 40

Drug Discovery World

FEBRUARY 5, 2024

To promote the immune response, the posology of biologics is usually high and requires intravenous injection, which raises safety concerns and significantly reduces patient compliance. Small molecules, such as BioSenic arsenic trioxide, that are active at very low doses and act on multiple intracellular pathways have a bright future.

Research 290

Research Small Molecule Clinical Trials Immune Response 290

Drug Discovery World

JULY 8, 2024

This RNA system is based upon the one-dimensional, linear structure of RNA and utilises a singular sequence of information, prompting the creation of viral protein and triggering an immune response to them.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

The Pharma Data

DECEMBER 27, 2020

Reporting encouraging preliminary Phase 1 clinical study results with VAC2 for the treatment of non-small cell lung cancer with high levels of antigen-specific immunogenicity observed.

Therapies 52

Therapies Production Clinical Trials Treatment 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

PerkinElmer

NOVEMBER 9, 2022

Immunotherapy has revolutionized cancer treatment and proved to be pivotal in the field of oncological research. These cells overexpress PD-L1, leading to inhibition of cytotoxic T-cells by binding to the PD-1 receptor on activated T-cells, and subsequent evasion of an immune response.

Small Molecule 52

Small Molecule Research Immune Response FDA Approval 52

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. By stopping or blocking the normal work of these molecules, diseases can often be slowed or even stopped.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. trial and we look forward to sharing T cell immune response data from the German trial in the near future.”. “It View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

Drug Discovery World

FEBRUARY 2, 2023

A variation on the master of none vs master of one theme is a single drug that targets several diseases (hence, master of many) but only inhibits a few targets; in the case of the small molecule known as RRx-001, those targets are subject to change depending on the local environmental conditions that are present in certain tissues or cells.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

Agency IQ

JUNE 9, 2023

Even so, nonclinical studies are generally expected to be complete prior to the initiation of Phase 3 clinical studies in which the product is evaluated in much larger human populations and/or for longer periods of treatment. Nonclinical studies encompass much more than just animal studies.

FDA 40

FDA Science Small Molecule Immune Response 40

The Pharma Data

DECEMBER 11, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. A breakdown of the diversity of clinical trial participants can be found here from more than 150 clinical trial sites in the U.S.,

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 7, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer- BioNTech COVID-19 Vaccine. anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

Drug Discovery World

OCTOBER 17, 2023

Analysing spatial changes during disease progression or treatment response is key to fully understand pathologies. BN : Yes, spatial analysis will help develop precision medicine, initially through advancing the speed of research and progression of therapeutic approaches and later as part of the treatment regime.

Disease 130

Disease Small Molecule Drugs RNA 130

New Drug Approvals

DECEMBER 16, 2023

3 Additionally, iptacopan has the benefit of targeting factor B, which only affect the alternative complement pathway, leaving the classic and lectin pathway untouched for the body to still mount adequate immune responses against pathogens. of patients experienced a sustained hemoglobin improvement without transfusions respectively.

FDA 62

FDA Small Molecule FDA Approval Treatment 62

The Pharma Data

JULY 21, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine. Procedures should be in place to avoid injury from fainting.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine. anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 10, 2020

The Phase 3 trial is designed as a 1:1 vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in the U.S.,

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

Drug Discovery World

APRIL 12, 2023

Testing new modality drugs poses additional challenges The drug development pipeline is no longer predominantly composed of small molecule drugs. Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the western world 4.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130